Literature DB >> 26603746

Burden of hypertension in China over the past decades: Systematic analysis of prevalence, treatment and control of hypertension.

Yixuan Wang1, Xiaoxia Peng2, Xiaolu Nie3, Li Chen4, Ryan Weldon4, Weili Zhang5, Dan Xiao6, Jun Cai7.   

Abstract

AIMS: To review comprehensively the prevalence, treatment and control of hypertension; and to estimate the burden of hypertension in China, thereby aiding Chinese health policies for better prevention and control of this condition. METHODS AND
RESULTS: PubMed, EMbase, China National Knowledge Infrastructure, Wanfang and Chongqing VIP databases were searched for population-based studies published in English and Chinese that described prevalence, treatment and control of hypertension in China, as well as deaths and disabilities attributed to hypertension. All research papers were published between January 1999 and May 2014. Data from 178 studies involving over 2,901,464 participants covering 30 provinces were pooled. Overall, rates of prevalence, treatment and control of hypertension were 28.9%, 35.3% and 13.4% in China. A statistically significant association was observed between temperature gradient and the prevalence of hypertension. There were 10,667 (95% confidence interval 8063-13,345) disability-adjusted life years per 100,000 people. In total, 78.3% of disability-adjusted life years were from years lived with disability and 21.7% from years of life lost due to premature mortality.
CONCLUSIONS: Although there has been a slight improvement in rates for the treatment and control of hypertension, these rates were still suboptimal, especially for men and people living in rural areas. Low and middle-income provinces had a comparatively huge burden of hypertension, which is a considerable risk factor for reducing life expectancy. Our analysis may be helpful in generating a current overview of hypertension in China. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Hypertension; burden of hypertension; control rate; prevalence; treatment rate

Mesh:

Year:  2015        PMID: 26603746     DOI: 10.1177/2047487315617105

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  28 in total

1.  SERS determination of the antihypertensive drugs prazosin and losartan by using silver nanoparticles coated with β-cyclodextrin.

Authors:  Jiawei Wu; Hao Ma; Xiangfeng Bu; Chao Ma; Lin Zhu; Baoqin Hao; Bing Zhao; Yuan Tian
Journal:  Mikrochim Acta       Date:  2019-11-18       Impact factor: 5.833

2.  Trends and Status of the Prevalence of Elevated Blood Pressure in Children and Adolescents in China: a Systematic Review and Meta-analysis.

Authors:  Lulin Wang; Lulu Song; Bingqing Liu; Lina Zhang; Mingyang Wu; Zhongqiang Cao; Youjie Wang
Journal:  Curr Hypertens Rep       Date:  2019-10-10       Impact factor: 5.369

3.  Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case-control study.

Authors:  S-Q Mao; J-H Sun; T-L Gu; F-B Zhu; F-Y Yin; L-N Zhang
Journal:  J Hum Hypertens       Date:  2017-03-16       Impact factor: 3.012

4.  Determination of antihypertensive drugs irbesartan and doxazosin mesylate in healthcare products and urine samples using surface-enhanced Raman scattering.

Authors:  Yanru Ding; Nan Zhang; Junqi Zhao; Haiyang Lv; Xu Wang; Bing Zhao; Yuan Tian
Journal:  Anal Bioanal Chem       Date:  2022-09-14       Impact factor: 4.478

5.  Association between sleep duration and hypertension in southwest China: a population-based cross-sectional study.

Authors:  Xiaoyu Chang; Xiaofang Chen; John S Ji; Guojin Luo; Xiaofang Chen; Qiang Sun; Ningmei Zhang; Yu Guo; Pei Pei; Liming Li; Zhengming Chen; Xianping Wu
Journal:  BMJ Open       Date:  2022-06-27       Impact factor: 3.006

6.  Socioeconomic differentials in trends in the prevalence of hypertension and pre-hypertension and hypertension awareness, treatment, and control in rural Southwestern China.

Authors:  Lu-Ming Fan; Fang Wang; Min Zhao; Wen-Long Cui; Le Cai
Journal:  BMC Cardiovasc Disord       Date:  2021-05-26       Impact factor: 2.298

7.  Prevalence and risk factors of hypertension among Hui population in China: A systematic review and meta-analysis based on 30,565 study participants.

Authors:  Yuanyuan Zhang; Xiangping Fan; Sijun Li; Yutan Wang; Sujie Shi; Huilan Lu; Fanghong Yan; Yuxia Ma
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

8.  Persistent effect at 30-month post intervention of a community-based randomized trial of KM2H2 in reducing stroke and heart attack among senior hypertensive patients.

Authors:  Jie Gong; Yunan Xu; Xinguang Chen; Niannian Yang; Fang Li; Yaqiong Yan
Journal:  Int J Behav Nutr Phys Act       Date:  2018-01-02       Impact factor: 6.457

9.  Poor management of hypertension is an important precipitating factor for the development of acute aortic dissection.

Authors:  Ning Dong; Hulin Piao; Bo Li; Jian Xu; Shibo Wei; Kexiang Liu
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-05-20       Impact factor: 3.738

10.  Association between plasma homocysteine and hypertension: Results from a cross-sectional and longitudinal analysis in Beijing's adult population from 2012 to 2017.

Authors:  Li-Xin Tao; Kun Yang; Jie Wu; Gehendra Mahara; Jie Zhang; Jing-Bo Zhang; Zhao Ping; Xiuhua Guo
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-10-26       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.